Kiniksa Pharmaceuticals International’s (KNSA) “Outperform” Rating Reaffirmed at Wedbush

Wedbush reiterated their outperform rating on shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) in a research report report published on Tuesday,RTT News reports. Wedbush currently has a $48.00 price target on the stock.

Other research analysts have also issued reports about the stock. Zacks Research lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Weiss Ratings restated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, October 8th. TD Cowen initiated coverage on Kiniksa Pharmaceuticals International in a research report on Monday, September 29th. They set a “buy” rating and a $60.00 target price on the stock. Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 2nd. Finally, Wells Fargo & Company upped their price objective on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an “overweight” rating in a research report on Thursday, September 25th. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $52.00.

Kiniksa Pharmaceuticals International Stock Performance

KNSA stock opened at $40.07 on Tuesday. Kiniksa Pharmaceuticals International has a fifty-two week low of $17.82 and a fifty-two week high of $42.98. The stock’s 50 day simple moving average is $39.26 and its 200 day simple moving average is $33.72. The company has a market cap of $3.04 billion, a P/E ratio of 89.05 and a beta of 0.02.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its earnings results on Tuesday, October 28th. The company reported $0.23 earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.The firm had revenue of $180.86 million for the quarter, compared to analyst estimates of $166.64 million. During the same period in the previous year, the company earned ($0.18) earnings per share. Kiniksa Pharmaceuticals International’s revenue for the quarter was up 61.2% compared to the same quarter last year. Equities analysts predict that Kiniksa Pharmaceuticals International will post -0.55 earnings per share for the current year.

Insider Activity at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, insider John F. Paolini sold 82,542 shares of the business’s stock in a transaction on Friday, October 31st. The stock was sold at an average price of $37.14, for a total value of $3,065,609.88. Following the sale, the insider directly owned 61,324 shares in the company, valued at $2,277,573.36. The trade was a 57.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO Michael R. Megna sold 50,490 shares of the company’s stock in a transaction on Monday, October 20th. The shares were sold at an average price of $38.87, for a total value of $1,962,546.30. Following the transaction, the chief accounting officer directly owned 27,046 shares in the company, valued at $1,051,278.02. This represents a 65.12% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 596,622 shares of company stock worth $22,697,248 over the last 90 days. Corporate insiders own 53.48% of the company’s stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Large investors have recently added to or reduced their stakes in the company. Rubric Capital Management LP boosted its stake in Kiniksa Pharmaceuticals International by 2.3% during the third quarter. Rubric Capital Management LP now owns 4,000,000 shares of the company’s stock valued at $155,320,000 after buying an additional 90,194 shares during the period. Vanguard Group Inc. lifted its position in Kiniksa Pharmaceuticals International by 4.7% during the first quarter. Vanguard Group Inc. now owns 3,359,101 shares of the company’s stock valued at $74,606,000 after purchasing an additional 151,604 shares during the last quarter. Acadian Asset Management LLC increased its holdings in shares of Kiniksa Pharmaceuticals International by 22.6% in the 2nd quarter. Acadian Asset Management LLC now owns 1,267,989 shares of the company’s stock worth $35,067,000 after buying an additional 233,668 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its position in shares of Kiniksa Pharmaceuticals International by 45.3% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,068,263 shares of the company’s stock valued at $41,481,000 after buying an additional 332,846 shares in the last quarter. Finally, Qube Research & Technologies Ltd raised its position in shares of Kiniksa Pharmaceuticals International by 277.8% during the 2nd quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after buying an additional 653,236 shares in the last quarter. Hedge funds and other institutional investors own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.